May 19, 2017 / 5:08 AM / 3 months ago

BRIEF-Santhera expects CHMP opinion about Raxone in Q3 2017

May 19 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG

* PROVIDES UPDATE ON TIMELINE FOR APPLICATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY IN EUROPE

* WE ARE NOW EXPECTING TO RECEIVE A REQUEST FOR SUPPLEMENTARY INFORMATION TO FURTHER SUPPORT CLINICAL RELEVANCE OF OUR DATA

* WE ARE WORKING CLOSELY WITH CHMP TO CONCLUDE APPLICATION PROCESS AND ANTICIPATE AN OPINION IN Q3 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below